Adagene partners with Incyte for cancer drug combination study
Go back to Adagene partners with Incyte for cancer drug combination study| (NASDAQ: ADAG) | Delayed: 3.31 +0.04 (1.22%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $3.27 | 52 Week High | $ | |||
| Open | $3.54 | 52 Week Low | $ | |||
| Day High | $3.55 | P/E | N/A | |||
| Day Low | $3.20 | EPS | $ | |||
| Volume | 224,590 | |||||
| Incyte Genomics, Inc. (NASDAQ: INCY) | Delayed: 123.28 -2.73 (2.17%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $126.01 | 52 Week High | $118.49 | |||
| Open | $125.09 | 52 Week Low | $55.00 | |||
| Day High | $126.31 | P/E | N/A | |||
| Day Low | $122.58 | EPS | $-0.56 | |||
| Volume | 1,462,891 | |||||
